GLP-1 Industry 2026 Outlook: Supply, Pricing, and Clinic Strategies

The GLP-1 industry has undergone dramatic change over the past three years. From the shortage-driven compounding boom of 2023–2024 to the supply stabilization and regulatory tightening of 2025, the landscape has shifted significantly. Here is the 2026 outlook and what it means for clinics.

Novo Nordisk and Eli Lilly have dramatically expanded manufacturing capacity for semaglutide and tirzepatide. Both companies removed their products from the FDA shortage list in 2025, which has significant implications:

• 503B bulk compounding restrictions: 503B outsourcing facilities can no longer compound copies of commercially available GLP-1s for office stock
• Increased regulatory scrutiny: The FDA has increased enforcement activity against compounders producing GLP-1s that are "essentially copies" of branded products
• 503A remains viable: Patient-specific 503A compounding with documented clinical rationale remains permissible

Despite the shortage list removal, the compounded GLP-1 market remains significant because:

• Branded products remain expensive ($900–$1,400/month retail)
• Insurance coverage is inconsistent
• Many patients cannot access or afford branded products
• Compounded preparations with clinical differentiation (additives, specific formulations) remain permissible under 503A

The compounded market has not disappeared — it has matured and become more compliance-focused.

Competition between Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) is creating pricing pressure on branded products. Both companies have introduced patient assistance programs and are negotiating with payers for broader coverage.

As more GLP-1 agents enter the market (retatrutide, oral semaglutide, oral tirzepatide), competitive pricing pressure will increase.

Compounded GLP-1 prices have stabilized after the volatility of the shortage period. Current market pricing for compounded semaglutide and tirzepatide is $150–$400/month depending on dose and supplier.

As the compounded market matures, price competition among compounders will likely increase. Practices that compete on price alone will face margin compression. Practices that compete on clinical quality, compliance, and service will maintain margins.

Oral semaglutide (Rybelsus) is already FDA-approved for T2D. Novo Nordisk is developing higher-dose oral semaglutide for obesity — Phase 3 data is expected in 2026–2027.

Eli Lilly is developing an oral formulation of tirzepatide. Early data is promising.

Oral GLP-1s will expand the addressable market — patients who are needle-averse or who prefer oral administration will have options. For clinics, this means:

• Larger potential patient population
• Need to offer both injectable and oral options
• Potential for lower-cost oral options to compete with injectable compounded products

In a market with increasing regulatory scrutiny, practices that have invested in compliance infrastructure are differentiated. Patients and referring providers are increasingly asking about compliance credentials.

Action: Document your supplier relationships, prescribing protocols, and compliance infrastructure. Make it visible to patients and referral sources.

GLP-1 alone is becoming commoditized. Practices that offer comprehensive metabolic health programs — GLP-1 + NAD+ + peptides + nutrition + monitoring — command premium pricing and higher patient retention.

Action: Build a comprehensive program, not just a prescription service.

Practices that invest in patient education and support have dramatically better retention. Patients who understand their therapy, know how to manage side effects, and feel supported are more likely to stay on therapy.

Action: Develop patient education materials, check-in protocols, and support systems.

Telehealth-enabled practices can serve patients across state lines, dramatically expanding the addressable market. With proper licensing and compliance infrastructure, a single practice can serve patients in all 50 states.

Action: Invest in telehealth infrastructure and multi-state licensing.

IRB-approved research participation differentiates practices as credible, evidence-based providers. It also provides access to emerging compounds and generates outcomes data.

Action: Explore IRB enrollment through MedClinic Partners.

Request portal access →

This content is for informational purposes only. Market projections are estimates and subject to change.